EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE Drug Patent Profile
✉ Email this page to a colleague
When do Emtricitabine And Tenofovir Disoproxil Fumarate patents expire, and when can generic versions of Emtricitabine And Tenofovir Disoproxil Fumarate launch?
Emtricitabine And Tenofovir Disoproxil Fumarate is a drug marketed by Hetero Labs Ltd Iii and is included in one NDA.
The generic ingredient in EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE is emtricitabine; tenofovir disoproxil fumarate. There are eighteen drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the emtricitabine; tenofovir disoproxil fumarate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Emtricitabine And Tenofovir Disoproxil Fumarate
A generic version of EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE was approved as emtricitabine; tenofovir disoproxil fumarate by TEVA PHARMS USA on June 8th, 2017.
Summary for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 176 |
Formulation / Manufacturing: | see details |
DailyMed Link: | EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE at DailyMed |
Recent Clinical Trials for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Assistance Publique - Hôpitaux de Paris, FRANCE | Phase 3 |
Ministry of Health, Thailand | Phase 3 |
Chiang Mai University, Thailand | Phase 3 |
See all EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE clinical trials
Pharmacology for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Anatomical Therapeutic Chemical (ATC) Classes for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
US Patents and Regulatory Information for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hetero Labs Ltd Iii | EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE | emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 201806-001 | Oct 7, 2021 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |